Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.
Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.
|Esperion Therapeutics (NASDAQ: ESPR)||2:22 PM ET on Apr 17, 2014|
|Last Price||Change||Open||Day High||52-Week High|
|Volume||Previous Close||Day Low||52-Week Low|